Aclaris Therapeutics entered the summer in an unfamiliar position: a clinical-stage biotech that the market had largely written off a few years ago, now trading near $6 - up roughly three and a half times from its 52-week low - with the most data-dense calendar in its history directly ahead. The second-quarter report is less about the quarter's own numbers than about what those numbers fund: three placebo-controlled readouts due in the second half of 2026. The first came early. In April, Aclaris reported positive top-line Phase 1a data for ATI-052, its anti-TSLP/IL-4R-alpha bispecific antibody, showing a ~45-day half-life and sustained pharmacodynamic engagement that management says supports dosing as infrequent as once a quarter. That result, more than any financial line, is why the stock has re-rated.
The tension is the funding. This is not a company quietly accumulating cash; it is one spending faster and raising to match. Research and development expense rose 58% year over year to $18.1 million in the quarter, the company's net loss widened to $21.5 million from $15.4 million, and first-half operating cash burn reached $38 million. Against that, Aclaris raised roughly $100 million of gross proceeds through its at-the-market facility across 2026 - about $60 million in March and another $40 million after June 30 - lifting cash and marketable securities to $170.6 million and buying a runway it says extends through the end of 2028. Every dollar of that runway was paid for in dilution. The shares outstanding grew roughly 29% year over year - almost entirely on the March at-the-market issuance - and were essentially flat in the second quarter itself.
So the investment question is a clean one. The valuation - roughly $871 million at the August 2026 close - now prices in much of the TSLP and ITK opportunity. What decides whether that price holds is a schedule of binary events: Phase 1b proof-of-concept results for ATI-052 in both atopic dermatitis and asthma, and the Phase 2 result for bosakitug (ATI-045) in 109 atopic-dermatitis patients, all expected before year-end. Each is a placebo-controlled, go-or-no-go test. The second half of 2026 is the readout; the question is whether the data meets the price.